SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human ...

The Company's organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services, and making life easier for the ...

limiting long-term revenue. Additionally, despite possessing one of the largest DNA databases globally, the company has secured only a few partnerships with pharmaceutical companies for medical ...

23andMe is considering a sale of the company ... DNA testing kits are mostly a one-time purchase, limiting long-term revenue. Additionally, despite possessing one of the largest DNA databases ...

Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business ...

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

23andMe ended December 31 ... or take other actions. Total Revenue for FY25 Q3 was $60.3 million, compared to $44.7 million for the same period in the prior year. The increase was primarily ...

23andMe has no debt on its balance sheet ... Such improvement was due to the reasons discussed above, primarily the Non-Recurring Revenue Recognition and the FY24 Q3 Impairment Charge.

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.